Products for Research Use Only
RegisterLogin

(S) -10-Hydroxycamptothecin

CAT: 0804-HY-N0095-01Size: 100 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-N0095-01Size:100 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
(S) -10-Hydroxycamptothecin (10-HCPT;10-Hydroxycamptothecin) is a DNA topoisomerase I inhibitor of isolated from the Chinese plant Camptotheca accuminata. (S) -10-Hydroxycamptothecin exhibits a remarkable apoptosis-inducing effect. (S) -10-Hydroxycamptothecin has the potential for hepatoma, gastric carcinoma, colon cancer and leukaemia treatment[1][2][3][4].
CAS Number
19685-09-7
Product Name Alternative
10-HCPT; 10-Hydroxycamptothecin
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Apoptosis; Topoisomerase
Type
Natural Products
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/_S_-10-Hydroxycamptothecin.html
Purity
99.74
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=CC5=CC(O)=CC=C5N=C4C3=C2)=O
Molecular Formula
C20H16N2O5
Molecular Weight
364.35
Precautions
H302, H315, H319
References & Citations
[1]Min Liu, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance . Journal of Drug Targeting.|[2]Min Liu, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance. J Drug Target, Early Online: 1–8|[3]Yu P, et al. Synthesis and preliminary anticancer evaluation of 10-hydroxycamptothecin analogs. Biol Pharm Bull. 2012;35 (8) :1295-9.|[4]Zhang XW, et al. Differentiation-inducing action of 10-hydroxycamptothecin on human hepatoma Hep G2 cells. Acta Pharmacol Sin. 2000 Apr;21 (4) :364-8.|[5]Zhang XW, et al. Differential regulation of P53, c-Myc, Bcl-2, Bax and AFP protein expression, and caspase activity during 10-hydroxycamptothecin-induced apoptosis in Hep G2 cells. Anticancer Drugs. 2000 Oct;11 (9) :747-56.|[6]Liu M, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance. J Drug Target. 2016;24 (5) :433-40.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Natural Products
Clinical Information
Phase 2
Isoform
Topo I

Related Products

CatalogName
HY-N0275-01(±) -10-Hydroxycamptothecin
HY-N0275R(±) -10-Hydroxycamptothecin (Standard)
HY-W665464(Rac) -7-Ethyl-10-hydroxycamptothecin
HY-N05729-Hydroxycamptothecin
HY-N2063-0112-Ethyl-9-hydroxycamptothecin
HY-165130-017 (S),10 (S) -DiHOME
HY-13028510 (S),17 (S) -DiHDHA
HY-145511-0110 (S) -HOME
HY-1455439 (S) 10 (S) 13 (S) -TriHOME
HY-W983371A10 (S) -Hydroxystearic acid

Alternative Products

CatalogName
GTR19175337-01(±) -10-Hydroxycamptothecin
N2591-2010-Hydroxycamptothecin
TB0033-100010-Hydroxycamptothecin(e)
BUP13827-01(S) -10-Hydroxycamptothecin
B4745-100(S)-10-Hydroxycamptothecin

Popular Products